Fagni F, Bettiol A, Talarico R, et al. - Researchers undertook this multicentre retrospective analysis to test secukinumab with respect to its effectiveness and safety among patients with a mucosal and articular Behçet’s phenotype resistant to conventional and biologic treatment. Of 15 patients included, 6 exhibiting a polyarticular involvement were managed with secukinumab 300 mg/month, while secukinumab 150 mg/month was implemented to treat all other cases. The achievement of a response (complete or partial) by 9 (66.7%) patients was reported at 3 months of follow-up, and this proportion further rose to 86.7% at 6 months, 76.9% at 12 months, 90.0% at 18 months and 100.0% following 24 months. Findings revealed the safety as well as effectiveness of secukinumab at a dose of 150 and 300 mg per month for the long-term treatment of this patient population. Superior complete mucosal and articular responses were achieved with secukinumab 300 mg/month, with no serious or dose-associated adverse effects.